A Rare Jamaican Strain Vs. Pancreatic Cancer

Share:

An article posted on the Health Europa site reports that a drug development firm, Flavocure, has been granted Orphan drug status to study the effects of the flavonoid Caflanone (FBL-03G) on the treatment of pancreatic cancer. The FDA granted this status, following scientific studies of Black Swan, the cannabis strain containing Caflanone. The research showed that in animals with pancreatic cancer, the treatment demonstrated effectiveness in treating tumors.

Jamaican Cannabis

Clinical trials of the treatment are expected to begin in the spring. Harvard University, the Pancreatic Cancer Network, and others have strongly endorsed the study. The article quotes the company’s co-founder, Clark Swanson, as saying, “We are optimistic that the trials will be successful, and thus far research has shown that Caflanone (FBL-03G) to be non-toxic. This is a departure from most drugs in clinical trials which typically carry risk for toxicity and side effects.”

Share:
Cannabis Magazine

1 comment

  1. Avatar
    james urban 19 February, 2020 at 07:36 Reply

    my wife has stage 4 pancreatic cancer she was diagnosed oct. 18 2018 she has been through 5fu chemo for almost a year it stopped working so they put her on gemzar and abrazin she is very interested in the upcoming black swan clinical trails coming in the spring please forward any information you may have on this thank you

Leave a reply

We gotta ask... Are you 21+? This website requires you to be 21 years of age or older. Please verify your age to view the content, or click "Exit" to leave.